Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
about
InfluenzaWhat Are the Most Powerful Immunogen Design Vaccine Strategies?Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 HemagglutininsAn Influenza HA and M2e Based Vaccine Delivered by a Novel Attenuated Salmonella Mutant Protects Mice against Homologous H1N1 Infection.Different Repeat Annual Influenza Vaccinations Improve the Antibody Response to Drifted Influenza StrainsAntibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1.Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donorsA Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release.Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies.The Individual and Population Genetics of Antibody Immunity.Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem.Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.From Original Antigenic Sin to the Universal Influenza Virus Vaccine.Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children.Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem.Vaccine approaches conferring cross-protection against influenza viruses.Functional interrogation and mining of natively paired human VH:VL antibody repertoires.Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Memory B Cells that Cross-React with Group 1 and Group 2 Influenza A Viruses Are Abundant in Adult Human Repertoires.Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.Structural insights into the design of novel anti-influenza therapies.Insights into the Structural Basis of Antibody Affinity Maturation from Next-Generation Sequencing.IL-15 enhances cross-reactive antibody recall responses to seasonal H3 influenza viruses in vitro.An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein.Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera.How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin.Development of a high-throughput assay to detect antibody inhibition of low pH induced conformational changes of influenza virus hemagglutinin.Structural analysis of influenza vaccine virus-like particles reveals a multicomponent organization.Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy.One-step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock-in miceTracing Antibody Repertoire Evolution by Systems PhylogenyAntibody Cross-Reactivity in Antivenom ResearchComplementary recognition of the receptor-binding site of highly pathogenic H5N1 influenza viruses by two human neutralizing antibodiesBeyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine DesignInfluenza, evolution, and the next pandemic
P2860
Q28066188-3E24C3D7-36D3-4B71-9545-4970C9943E54Q28729792-2C8401FD-73BF-48D4-BAF9-44015C345632Q30392944-552F20D9-B357-4F21-B1CD-72F048F67C5DQ33679360-7D2E3B46-79DF-48F2-B16A-29025FA489FBQ33899438-34C952F7-95C6-430E-BB2B-ABA0C16F3398Q36263513-84F29C81-E162-4C92-82FE-588E4FCD4F8AQ37593886-6395AECA-1163-41A5-B990-FCBE6C0C618BQ37714300-9B0245B1-5BEC-4205-8AE9-26A16B869825Q38636861-11A2F04B-630B-4CCD-AD52-BF0F9416432CQ38652483-E53653C4-308C-4798-8255-7B1497F02DF1Q38766578-035895DF-DB82-4516-A54E-DB271F968F86Q39108730-872887F8-4BB8-4545-AAC8-303E93FA51DAQ40056179-B4C7CF48-C5D7-4F85-A8AB-3F7F086F0EF2Q40059787-3BBCB6F5-9D74-4402-A946-1E60BD3C40EEQ40082914-E8446F55-9E4D-4DF5-9FB8-460F9AC9336FQ41933744-FA172782-7724-456C-A48A-68323B3E19C8Q41934895-B1180E19-854C-4DD8-B493-25374279F9E0Q47194745-1E42C4C5-9BE1-4AAC-84A4-1A454BB39DCBQ47548101-740BB7AB-2FCD-4351-8E52-0A0EF949CD4FQ47552319-F9D88D81-34AD-4117-9837-37E83390DA45Q47570091-92FC3044-2B48-451C-A5F3-F3BB7EE9ABDCQ48113181-6F1A48E7-D8D8-4A83-BE26-0F4DFF93D061Q49956907-179BA8CD-5541-485D-974B-90B8A42D4217Q50534689-A38CD878-BD02-4EB8-BAB7-D7404E172644Q52317335-29B14654-61B1-4CF4-95B5-7BEE30C6DF5CQ53700367-7018E90C-9FB4-4CA1-8B59-5F0FD104F8EFQ55312137-F5B3D3F1-0C53-4146-A016-7A345069D844Q55318229-1D64CBC6-BA10-4F95-B096-68801E2EE9A2Q55501368-37998146-8224-49A3-B4AC-1B30712B20C9Q55627667-AA10E17B-F1AE-4F47-9BE3-F055BB41DFBCQ55689231-3806F475-C192-4882-8190-F4DFC2AE82CAQ57157197-64484E49-E58A-4B52-9B48-C4ED45C5D6EDQ58586481-7DE0928E-1ABC-4678-93C0-BE8C15F1A28DQ58646919-FC667C0D-4EC6-408F-8DEA-A2564DA9701DQ58696897-7A38E634-C36E-4BA5-B64B-795EB899443BQ58781552-A58D031B-C3A9-4F57-9A0D-B1EDB9316307Q59136752-EECD27DA-12FA-415F-BB25-3212B5764194
P2860
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@ast
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@en
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@nl
type
label
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@ast
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@en
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@nl
prefLabel
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@ast
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@en
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@nl
P2093
P2860
P50
P3181
P1433
P1476
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
@en
P2093
Adrian B McDermott
Aliaksandr Druz
Amy Ransier
Baoshan Zhang
Celia Santos
Chen-Hsiang Shen
Christopher R Lees
Daniel C Douek
Eun Sung Yang
Gwo-Yu Chuang
P2860
P304
P3181
P356
10.1016/J.CELL.2016.06.043
P407
P50
P577
2016-07-28T00:00:00Z